HOME >> BIOLOGY >> NEWS
Sea Grant researchers isolate new antibiotic from fish

Raleigh, N.C. North Carolina Sea Grant researchers are reporting the discovery of a new peptide antibiotic in fish that may have implications for treating diseases in both humans and animals, according to the November 15th issue of the peer-review journal, Nature.

Named piscidins after the Latin term "pisces" for fishes, the antibiotics were isolated from mast cells in hybrid striped bass. Mast cells are the most common tissue immune cell found in fish and other vertebrates, including humans. They are present in many tissues, including the skin, gills, and gastrointestinal tract. This is the first time that researchers have isolated a peptide antibiotic from mast cells of any animals, including humans. However, it is unclear whether fish mast cells are from the same lineage as mammal mast cells.

"The peptide antibiotics or piscidins have the potential to fight important bacterial pathogens of both fish and mammals, including multi-drug resistant bacteria," said Ed Noga, professor at the North Carolina State University College of Veterinary Medicine, and head of the research team that made the discovery.

"The antibiotics could be a useful template for designing new drugs because they are novel structures and not related to any known and currently used antibiotic," notes Noga. "With the development of antibiotic-resistant bacteria, there is an urgent need to find new types of antibiotics that can fight these resistant pathogens."

"While mast cells are one of the most common immune cells of vertebrates, their role as a critical line of defense has been uncertain," he added. "However, if any type of peptide antibiotic is also present in human mast cells, it could have important implications for treating human diseases, including asthma, skin allergies and certain types of arthritis, because of the prominent role that mast cells play in these diseases."

North Carolina Sea Grant Director Ron Hodson points out that the research
'"/>

Contact: Ed Noga
ed_noga@ncsu.edy
919-515-6236
National Sea Grant College Program
14-Nov-2001


Page: 1 2

Related biology news :

1. Grant advances biochemical engineering laboratory
2. GlaxoSmithKline Drug Discovery and Development Research Grant Program 2004
3. Grant from GE Foundation to University of Houston to strengthen math, tech pipeline
4. McGill Centre for Intellectual Property Policy receives $3 million SSHRC Grant
5. Grant promotes marine ornamental fish aquaculture
6. Grant of powerful computer to Rutgers-Newark will increase understanding of brain activity
7. Grant renews funding of research toward cloning primates
8. Lipids get the spotlight in new NIGMS Glue Grant
9. Grant funds research to develop tissue-engineered solutions for heart disease
10. Grant strengthens research arm of Penn State Hershey Medical Centers ALS Clinic
11. Sea Grant News & Notes for March 26, 2003

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Sea Grant researchers isolate new antibiotic from fish

(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 30, 2015    Intrexon Corporation (NYSE: ... and Merck Serono, the biopharmaceutical business of Merck ... announced an exclusive strategic collaboration and license agreement ... (CAR-T) cancer therapies. This collaboration advances Merck Serono,s ... modulate the immune system,s natural ability to fight ...
(Date:3/30/2015)... and BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... in Europe and the United States and plenary talks ... planned for SPIE Optics + Optoelectronics next ... over 700 technical presentations in 17 conferences alongside a ... for optics and photonics , the event will run ...
(Date:3/30/2015)... 30, 2015  Naldemedine, an investigational peripherally acting ... & Co., Ltd., met its primary and secondary ... for the treatment of opioid-induced constipation (OIC) in ... therapy. Study results showed that naldemedine (0.2 mg ... frequency of spontaneous bowel movement (SBM) compared with ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: